TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock Price

TLSIStock

$4.83−5.48%52W

Market Cap$297.41M

P/E—

PEG Ratio—

Div yield—

Beta0.42

TLSI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.14%

Price vs S&P 500 (4W)0.14%

VGM Score45.64

Book Value / Share (Quarterly)$0.21

P/TBV (Annual)16.11x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.33

Price vs S&P 500 (YTD)-43.62%

Gross Margin (TTM)85.07%

Net Profit Margin (TTM)-60.85%

EPS (TTM)$-0.68

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-0.68

EPS (Annual)$-1.04

ROI (Annual)71.03%

Gross Margin (Annual)84.57%

Cash / Share (Quarterly)$0.92

Revenue Growth QoQ (YoY)-2.92%

ROA (Last FY)-111.03%

Revenue Growth TTM (YoY)39.64%

EBITD / Share (TTM)$-0.63

Operating Margin (TTM)-62.45%

Cash Flow / Share (Annual)$-0.38

P/B Ratio23.70x

P/B Ratio (Quarterly)19.18x

Net Income / Employee (Annual)$-384,600

EV / Revenue (TTM)6.24x

Net Interest Coverage (TTM)-6.86x

ROA (TTM)-59.35%

EPS Incl Extra (Annual)$-1.04

Current Ratio (Annual)2.80x

Quick Ratio (Quarterly)5.24x

3-Month Avg Trading Volume0.39M

52-Week Price Return-5.48%

EV / Free Cash Flow (Annual)19.22x

Revenue / Employee (TTM)$440,000

Tangible BV / Share (Quarterly)$0.28

P/S Ratio (Annual)6.72x

Asset Turnover (Annual)1.28x

52-Week High$7.95

EPS Excl Extra (Annual)$-1.04

26-Week Price Return-9.21%

Quick Ratio (Annual)2.35x

13-Week Price Return47.71%

Total Debt / Equity (Annual)0.20x

Current Ratio (Quarterly)5.78x

Enterprise Value$280.09M

Asset Turnover (TTM)0.98x

Revenue / Employee (Annual)$442,700

Pretax Margin (Annual)-86.86%

Cash / Share (Annual)$0.41

3-Month Return Std Dev73.87%

Net Income / Employee (TTM)$-267,800

ROE (Last FY)85.23%

Net Interest Coverage (Annual)-4.33x

EPS Basic Excl Extra (Annual)$-1.04

Receivables Turnover (TTM)8.41x

EV / Free Cash Flow (TTM)46.64x

Total Debt / Equity (Quarterly)2.58x

EPS Incl Extra (TTM)$-0.68

ROI (TTM)3.35%

P/S Ratio (TTM)6.76x

Revenue / Share (Annual)$1.19

Tangible BV / Share (Annual)$0.80

Price vs S&P 500 (52W)-24.04%

Year-to-Date Return-30.80%

5-Day Price Return-5.48%

EPS Normalized (Annual)$-1.04

ROA (5Y Avg)-89.67%

Net Profit Margin (Annual)-86.88%

Month-to-Date Return6.39%

Cash Flow / Share (TTM)$0.09

EBITD / Share (Annual)$-0.69

Operating Margin (Annual)-59.68%

LT Debt / Equity (Annual)0.20x

LT Debt / Equity (Quarterly)2.58x

EPS Basic Excl Extra (TTM)$-0.68

P/TBV (Quarterly)17.74x

P/B Ratio (Annual)5.02x

Inventory Turnover (TTM)1.69x

Pretax Margin (TTM)-60.84%

Book Value / Share (Annual)$0.80

Price vs S&P 500 (13W)45.75%

Beta0.42x

Revenue / Share (TTM)$0.86

ROE (TTM)12.02%

52-Week Low$2.20

vGradeD

gGradeC

mGradeC

vgmGradeC

TLSI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.15	-$0.16	-3.23%(-$0.01)
Q4 2025	Mar 5, 2026	-$0.13	-$0.05	+61.46%(+$0.08)
Q3 2025	Nov 13, 2025	-$0.17	-$0.87	-425.70%(-$0.70)
Q2 2025	Aug 12, 2025	-$0.22	-$0.23	-2.80%(-$0.01)

TLSI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.09

4.10

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
TLSITriSalus Life Sciences, Inc. Common Stock	D	C	C	$4.83
SYKStryker Corporation	C	B	C	$330.69
MMM3M Company	C	D	C	$174.34
BSXBoston Scientific Corp.	C	B	D	$46.84
BDXBecton, Dickinson and Co.	B	D	B	$189.52
MDLNMedline Inc. Class A common stock	C	D	C	$35.28
RMDResMed Inc.	C	B	B	$240.33
DXCMDexCom, Inc.	D	B	B	$90.82
WSTWest Pharmaceutical Services, Inc.	D	C	B	$337.47
SOLVSolventum Corporation	C	C	B	$91.12
BAXBaxter International Inc.	B	D	B	$26.13
PENPenumbra, Inc.	D	C	C	$321.68
GMEDGLOBUS MEDICAL INC	B	B	C	$82.97
GKOSGlaukos Corporation	F	A	A	$179.87
PODDInsulet Corporation	C	A	C	$145.13
TFXTeleflex Incorporated	B	F	B	$139.67
STVNStevanato Group S.p.A.	D	C	C	$21.03
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$20.10
MMSIMerit Medical Systems Inc	C	B	B	$90.49
HAEHaemonetics Corporation	C	C	A	$103.96
ICUIICU Medical Inc	C	D	B	$175.10
HTFLHeartflow, Inc. Common Stock	—	A	B	$47.78
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$120.25
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$47.57
ATRCAtriCure, Inc.	D	B	B	$48.54
UFPTUFP Technologies Inc	C	B	B	$300.05
NVCRNovoCure Limited Ordinary Shares	D	C	B	$17.82
LMATLeMaitre Vascular, Inc.	C	B	C	$80.45
INSPInspire Medical Systems, Inc.	B	B	B	$61.44
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$25.64
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.43
ATECAlphatec Holdings, Inc.	D	B	C	$9.44
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.64
IARTIntegra LifeSciences Holdings	B	D	B	$16.89
AORTArtivion, Inc.	C	C	C	$26.77
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$20.83
IRMDiRadimed Corporation	D	B	C	$87.07
BVSBioventus Inc. Class A Common Stock	B	C	A	$13.84
BBNXBeta Bionics, Inc. Common Stock	D	A	B	$19.72
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.42
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.21
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.48
MDXGMiMedx Group, Inc	C	D	C	$4.50
ANGOAngioDynamics, Inc.	C	D	A	$15.85
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$23.65
BWAYBrainsway Ltd. American Depositary Shares	F	A	B	$14.30
DCTHDelcath Systems Inc	D	B	A	$16.34
CERSCerus Corp	D	C	B	$2.65
TCMDTactile Systems Technology, Inc.	B	B	C	$23.16
NPCENeuropace, Inc. Common Stock	D	C	B	$14.41
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$15.55

About TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics for difficult-to-treat hepatocellular and pancreatic cancers. The company commercializes PEDD infusion systems through its TriNav platform with SmartValve technology, while advancing the investigational agent nelitolimod (SD-101) to enhance immune response in liver and pancreatic cancer patients.